TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Post-ERCP Pancreatitis by Indomethacin Vs Diclofenac

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-90 years old patients planned to undergo ERCP~Exclusion Criteria:~* Allergy to NSAIDs~* The administration of NSAIDs within 7 days~* Not suitable for NSAIDs administration (gastrointestinal hemorrhage within 4 weeks, renal dysfunction \[Cr \>1.4mg/dl=120umol/l\]; presence of coagulopathy before the procedure)~* Previous biliary sphincterotomy and papillary large balloon dilation~* Acute pancreatitis within 3 days before ERCP~* Hemodynamical instability~* Pregnancy or lactation~* Unable to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- diclofenac group (Type: EXPERIMENTAL): Patients without contraindications in diclofenac group received 100mg rectal diclofenac 30 mins before ERCP procedure.
- Indomethacin group (Type: ACTIVE_COMPARATOR): Patients without contraindications in indomethacin group received 100mg rectal indomethacin 30 mins before ERCP procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: In Vitro Fertilization Outcomes of Two Treatment Protocols in Women With Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PCOS women undergoing ICSI cycles~* All women will be administered 150 IU rec FSH~Exclusion Criteria:~* Women having other endocrinopathies~* women older than 35~* third IVF/ICSI cycles~* previous and current use of metformin

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- GnRH Agonist (Type: ACTIVE_COMPARATOR): oral contraceptive pill and GnRH Agonist IVF/ICSI cycle
- GnRH Agonist Arm (Type: ACTIVE_COMPARATOR): Oral contraceptive pill and day 21 GnRH agonist began, Day 3 of menstruation 150 IU FSH will be started. If 3 or more follicle reach \>17 mm hCG will be administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Oxygen Saturation During Different Intraoperative Positions

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing lateral decubitus lung surgery or port-access.~* American Society of Anesthesiologists Physical Status (ASA) II or III.~* Age between 18-80 years.~* Patients willing to sign consent.~Exclusion Criteria:~* Pre-existing interstitial lung disease.~* Pre-existing obstructive airway disease.~* Inability or unwillingness of study participant to give written informed consent.~* Patients expected to have a difficult intubation for anatomical reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- lung surgery (Type: ACTIVE_COMPARATOR): An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. If necessary, measures are taken to maintain oxygenation during one lung ventilation.
- port-access cardiac surgery (Type: ACTIVE_COMPARATOR): An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. In the port-access group, FIO2 is maintained on 1 after the stopping of the ECC, so PaO2 will become our only indicator for oxygenation. If necessary, measures are taken to maintain oxygenation during one lung ventilation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Wearable, Battery-free Screening System for SARS-CoV-2, the Virus Causing COVID-19 Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~°Admission for definite or suspected SARS-CoV-2 infection with mild to moderate symptoms and clinical features.~If insufficient numbers of suspected cases who test negative, individuals admitted with other respiratory problems: COPD exacerbation, viral pneumonia, congestive heart failure who test negative for SARS-CoV-2 will be eligible as controls.~* Able to give informed consent.~* Access to a smartphone capable of downloading the study app and of collecting and transmitting study data.~* Ability to comply with study procedures.~* Ability to self-deploy the study devices and collect study data.~Exclusion Criteria:~* Inability to give informed consent.~* Allergic history to components of study devices,~* Inability to participate in study procedures.~* Severe disease or admission to a critical care unit.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet DSM-5 criteria for MA use disorder~* Be fluent in English and able to understand the consent form~Exclusion Criteria:~* Have an alcohol use disorder or report binge drinking (\>7 drinks for women and \>14 drinks for men)~* Have a greater than mild substance use disorder on any other illicit substance~* Have any medical conditions contraindicating SUVO (e.g., severe pulmonary disease, severe cardiovascular disease or clinically abnormal ECG, severe liver or kidney disease, seizure disorder, or sleep disorder - particularly narcolepsy)~* Are currently taking medications with known drug interactions with SUVO (e.g., MAO inhibitors, anticonvulsants, haloperidol, phenothiazines, anesthetics, and any sedative)~* Are pregnant or breast feeding~* BMI \> 30 (women only)~* Have a current DSM-5 psychiatric disorder or neurological disease requiring on-going treatment that would make participation unsafe~* Have history of seizure disorder~* Have a head injury with loss of consciousness in the last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 week Placebo then 1 week SUVO (Type: EXPERIMENTAL): After 1 week of placebo treatment there will be 1 week of wash out period before start of study medication
- 1 week SUVO then 1 week Placebo (Type: EXPERIMENTAL): After 1 week of SUVO treatment there will be 1 week of wash out period before start of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nutrition and Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified Prostate Cancer (at any stage)~* Scheduled to be treated by radical prostatectomy within the next 4-10 weeks~* Understanding and willingness to provide consent~Exclusion Criteria:~* Previous (within 6 months of enrollment) or concurrent hormonal therapy or chemotherapy; specifically, treatment with 5-alpha reductase inhibitors (finasteride and dutasteride)~* History of hormone dependent malignancies~* Concomitant thyroid disease or currently taking thyroid hormone replacement medication~* Current high-dose soy consumption, micronutrient, or herbal supplements, on soy or vegetarian nutrition, or any other extreme dietary habits~* Current or past history of any liver or pancreas disease~* History of allergy or hypersensitivity to soy-containing products~* Malabsorption conditions that might interfere with absorption of the investigational product

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Daily Fermented Soy (two 12.5g packets/day) (\~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
- Placebo (Type: PLACEBO_COMPARATOR): Daily (matched dose) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CT Guided Injection for Low Back Radiculopathy: A Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults \<60y~* \< 1m of symptoms~* Symptoms consistent with herniated disc~* MRI demonstrates corresponding disc~* Back pain resulting in functional disability~Exclusion Criteria:~* Chronic pain~* Daily pain medication~* Frequent back pain~* On the job injury

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- CT-guided intervention (Type: EXPERIMENTAL): CT guided perineural injection of corticosteroid+ bupivicaine Also get typical medical care
- Standard medical care (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intraarticular Corticosteroid Therapy in Perthes Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age of 4 to 12 years~* diagnosed with Idiopathic osteonecrosis of the femoral head~* symptoms less than 12 months old.~Exclusion Criteria:~* Symptoms for more than 12 months~* Previous treatment other than anti-inflammatories, crutches or bed rest~* Subjects more than 8 years old or have a hand bone age greater than 6 years old and lateral pillar B or B/C disease.~* Bilateral hip disease~* Personal or family history of problems with general anesthesia~* Prior steroid treatment~* Previous diagnosis of:~  * Asthma~ * Identifiable rheumatologic condition~ * Metabolic Diseases (including but not limited to Gaucher's disease or congenital hypothyroidism)~ * Sickle cell disease~ * Known pain syndrome~ * Hip sepsis~ * Prior malignancy (solid organ or bone marrow transplant)~ * Blood Clotting disorder

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- Injection (Type: EXPERIMENTAL): Patients in this arm receive one single dose of Triamcinolone hexacetonide injectable suspension (Aristopan), USP, 20mg/mL Parenteral. They will aso be enrolled in physical therapy.
- Control (Type: NO_INTERVENTION): Patients will be enrolled in physical therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Biopsy proven or clinically documented metastatic breast cancer with at least one lesion outside the liver by standard imaging (e.g. CT, MRI, Bone Scan, Ultrasound, FDG PET/CT)~* Plan to start new systemic therapy for metastatic disease.~* Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.~Exclusion Criteria:~* Females who are pregnant at the time of screening will not be eligible for this study, urine or serum pregnancy test will be performed in women of child-bearing potential at the time of screening.~* Inability to tolerate imaging procedure in the opinion of an investigator or treating physician.~* Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy of Manual Therapy for a Subgroup of Acute Non-specific Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* non specific acute low back pain \< 16 days,~* no pain below the knee,~* mobility deficit~Exclusion Criteria:~* specific low back pain (red flags),~* subacute or chronic non-specific LBP,~* previous history of surgery,~* high irritability,~* hyperlaxity - aberrant movement when standing flexion,~* post part um and pregnancy

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- spinal manipulation intervention group (Type: ACTIVE_COMPARATOR): Spinal manipulation: 3 sessions within one week of true lumbopelvic manipulation
- Spinal manipulation control group (Type: SHAM_COMPARATOR): Sham spinal manipulation: 3 sessions within one week of sham lumbopelvic manipulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Peroperative Assessment of Tumour Resection Margins Using High-resolution 18F-FDG-PET/CT in Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (≥ 18 years)~* Signed informed consent~* Patient with a Pancreas Ca who is undergoing Whipple surgery~* Patient with ASA grade 1 to 3~Exclusion Criteria:~* Patient has ASA 4~* Patient under long-term use of anticoagulant therapy (except low dose aspirin)~* Patient has tumor invasion of blood vessels~* The patient undergoes a total pancreatectomy~* Patient undergoes a double derivation~* pregnant or breastfeeding woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- test group (Type: OTHER): All patients who give their consent for this study will participate in the test group and will therefore receive the injection with 18F-FDG and images (PET / CT) will be made of the resection piece.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Sedation and Psychopharmacology in Critical Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: Patients aged 18 and older undergoing mechanical ventilation via naso- or orotracheal tube -~Exclusion Criteria: Age less than 18, tracheotomy, severe dementia or mental retardation, severe neuromuscular disease or neuromuscular blockade use, institution of mechanical ventilation at another hospital~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Periodontitis and Tooth Loss in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Fulfilling the 1987 revised criteria for the classification of Rheumatoid arthritis~* Under active follow-up by a rheumatologist at the Dudley Group of Hospitals~* Participation in study 04/Q2702/18 Establishment of an inception cohort for the prospective evaluation of predictors of cardiovascular morbidity and mortality in patients with rheumatoid arthritis.~* Participation in study 04/Q2702/18 A prospective study of micro and macro vascular disease in a cohort of patients with Rheumatoid arthritis).~* Written informed consent~Exclusion Criteria:~* No absolute exclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with rheumatoid arthritis (Type: None): The inception cohort of 400 patients will be followed up for 20 years following recruitment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically confirmed MCM or ALM that is metastatic or unresectable.~* Patients must be eligible to receive nivolumab in combination with ipilimumab treatment per institutional guidelines.~* Patients must have a tissue block (or 20 unstained slides) available with adequate tumor to perform multiplex immunohistochemistry and nucleic acids analyses ( i.e. whole exome sequencing) Patients with only a previous fine-needle aspirate are ineligible for enrollment.~* Patients must be willing to donate a small amount of whole blood prior to treatment and during treatment for laboratory analysis.~* Patients must give informed consent prior to initiation of therapy.~* Patients must be ambulatory with good performance status (ECOG 0 or 1)~Exclusion Criteria:~* Patients who do not have available tissue for immunohistochemistry and nucleic acids analyses.~* Patients who have received prior immunotherapy for unresectable or metastatic disease.~* Patients with untreated brain metastases, leptomeningeal disease, or seizure disorders are ineligible. Patients with a history of brain metastases must have completed treatment (i.e. surgery or radiation) 1 month prior to enrollment and have no evidence of disease or edema on brain CT or head MRI.~* Patients with inadequate tissue for analysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab-Ipilimumab Combination Therapy (Type: EXPERIMENTAL): All patients will receive nivolumab administered IV over 60 minutes at 1 mg/kg combined with ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks until progression, intolerable toxicity, or a maximum of 48 weeks, whichever comes first (Maintenance). Patients exhibiting complete response (CR) should continue nivolumab monotherapy at least 12 weeks beyond documentation of CR, if possible.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues